Comprehensive guide to Lactulose (ATC A06): a osmotic laxative for constipation and hepatic encephalopathy treatment with proven clinical efficacy.
Browse our catalog for available pharmaceutical products and competitive pricing.
Lactulose is a semi-synthetic disaccharide compound classified under ATC code A06 (drugs for constipation), widely recognized as an osmotic laxative and ammonia-reducing agent. It was first synthesized in 1957 and has since become a cornerstone medication in gastroenterology and hepatology. Lactulose is derived from lactose through enzymatic isomerization, creating a unique molecule that the human body cannot absorb or metabolize efficiently.
This pharmaceutical compound exists as a clear, colorless to pale yellow solution with a slightly sweet taste, making it relatively palatable for patients. Lactulose is non-systemic, meaning it works locally within the gastrointestinal tract without significant absorption into the bloodstream. It is produced by numerous pharmaceutical manufacturers worldwide and is available under various brand names, making it accessible and affordable for patients across different healthcare systems.
The clinical significance of Lactulose extends beyond simple constipation relief. Its unique mechanism of action addresses multiple pathophysiological conditions, particularly in patients with liver disease, making it an invaluable therapeutic option in both primary care and specialized medical settings.
Lactulose operates through multiple interconnected mechanisms that contribute to its therapeutic benefits. When ingested, Lactulose passes largely unabsorbed through the stomach and small intestine due to its chemical structure, which human digestive enzymes cannot readily break down. Upon reaching the colon, resident bacterial flora ferment Lactulose, producing organic acids (primarily acetic and lactic acid) and gases. This fermentation process reduces colonic pH, creating an acidic environment that contributes to several therapeutic effects. The organic acids draw water into the intestinal lumen through osmotic action, softening stool and promoting bowel movements. Additionally, the acidic environment and bacterial fermentation byproducts suppress ammonia-producing bacteria, reducing ammonia absorption—a critical factor in managing hepatic encephalopathy.
Lactulose demonstrates clinical efficacy across multiple gastrointestinal and hepatic conditions. Its dual mechanism—as both an osmotic laxative and ammonia-reducing agent—makes it suitable for treating constipation and managing complications of liver disease. Healthcare providers select Lactulose based on patient-specific factors including age, renal function, underlying comorbidities, and disease severity.
Lactulose is available in liquid formulation (solution) and should be administered orally. Dosing is highly individualized, titrated based on patient response and tolerance. The goal is typically to achieve 1-2 soft bowel movements daily. Initial doses are often conservative, with gradual escalation to minimize adverse gastrointestinal effects. Patients should maintain adequate hydration throughout treatment, as osmotic laxatives increase fluid requirements.
| Indication | Typical Dose | Frequency | Route |
|---|---|---|---|
| Chronic constipation (adult) | 15-30 mL | Once or twice daily | Oral |
| Hepatic encephalopathy (acute) | 30-45 mL | Three times daily, then titrate | Oral |
| Hepatic encephalopathy (maintenance) | 15-30 mL | Two to three times daily | Oral |
| Pediatric constipation | 5-10 mL per day | Once or twice daily | Oral |
Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Lactulose typically begins to exert effects within 24-48 hours, though some patients experience response within 6-12 hours. Dose adjustments should be made gradually over several days to allow patient tolerance adaptation.
Lactulose has a favorable drug interaction profile due to its minimal systemic absorption. However, several important interactions warrant clinical consideration. Since Lactulose is not absorbed and does not undergo hepatic metabolism, it does not inhibit or induce cytochrome P450 enzymes. Nevertheless, osmotic effects and altered gastrointestinal transit can influence the absorption of other orally administered medications.
Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.
Yes, Lactulose is generally considered safe for long-term use, with many patients taking it chronically without significant adverse effects. Unlike stimulant laxatives, Lactulose does not cause dependency or loss of colonic muscle tone. However, long-term use requires periodic monitoring of electrolytes, particularly potassium and sodium levels, especially in elderly patients or those with renal disease. Your healthcare provider should periodically reassess the continued need for Lactulose and evaluate for alternative etiologies of constipation.
Lactulose can be taken with or without food; food does not significantly impair absorption since Lactulose is minimally absorbed. However, taking Lactulose with food may help minimize initial nausea or gastrointestinal discomfort in sensitive patients. Some clinicians recommend taking Lactulose with a meal to improve tolerance. Consistency in timing is more important than food presence; establish a regular administration schedule and maintain it.
If you miss a dose of Lactulose, take it as soon as you remember, unless it is nearly time for your next scheduled dose. Do not double-dose to make up for a missed dose. Lactulose works cumulatively over 24-48 hours, so occasional missed doses will not significantly impact efficacy. If you frequently miss doses, discuss alternative dosing schedules or formulations with your healthcare provider to improve medication adherence.